RTI uses cookies to offer you the best experience online. By and clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Accept
  • Home
  • Impact
  • Publications
  • Treatment interruptions and regimen changes in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia

Treatment interruptions and regimen changes in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia

Ward, M., Fang, G., Richards, K., Walko, C., Earnshaw, S., & Happe, L. (2015). Treatment interruptions and regimen changes in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. Journal of Health Economics, 2(2), 181-91.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Cannabis use in college
Article

Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism
OCCASIONAL PAPER

Agreements between public health organizations and food and beverage companies
Article

Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features